阿立哌唑联合无抽搐电休克治疗难治性精神分裂症的临床效果观察  

Clinical effects of aripiprazole combined with modified electric convulsive therapy in the treatment of refractory schizophrenia

作　　者：戴艺荣 叶小惠 DAI Yi-rong;YE Xiao-hui(Department of Psychiatry,Nan'an Rehabilitation Hospital,Quanzhou 362300,China)

机构地区：[1]泉州市南安市康复院精神科,362300

出　　处：《中国现代药物应用》2024年第7期29-33,共5页Chinese Journal of Modern Drug Application

摘　　要：目的研究阿立哌唑联合无抽搐电休克治疗难治性精神分裂症患者的临床效果。方法86例难治性精神分裂症患者,以随机数字表法分为试验组及对照组,每组43例。两组均行阿立哌唑药物治疗,试验组在此基础上行无抽搐电休克治疗。比较两组治疗效果、症状评分(阳性症状、阴性症状、一般精神病理评分)、血清神经营养因子[脑源性神经营养因子(BDNF)、神经生长因子(NGF)、神经营养因子-3(NT-3)]、血清炎症因子[白细胞介素-4(IL-4)、白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)]、不良反应发生率。结果试验组的治疗优良率69.77%高于对照组的41.86%(P<0.05)。治疗后,两组的阳性症状、阴性症状、一般精神病理评分及总分低于治疗前,且试验组的阳性症状、阴性症状、一般精神病理评分及总分分别为(15.51±2.64)、(13.62±2.88)、(22.53±5.82)、(51.66±6.78)分,低于对照组的(20.21±5.47)、(18.69±4.75)、(27.66±7.82)、(66.56±9.24)分(P<0.05)。治疗后,两组的BDNF、NGF、NT-3水平高于治疗前,且试验组的BDNF(14.05±2.56)μg/L、NGF(46.77±9.21)μg/L、NT-3(170.82±22.61)pg/ml高于对照组的(11.18±1.97)μg/L、(38.69±8.41)μg/L、(151.63±20.74)pg/ml(P<0.05)。治疗后,两组的IL-4水平高于治疗前,IL-6、IL-1β水平低于治疗前,且试验组的IL-4(11.35±3.58)pg/ml高于对照组的(9.52±2.64)pg/ml,IL-6(30.31±3.64)pg/ml、IL-1β(26.85±3.62)pg/ml低于对照组的(41.49±5.73)、(35.85±4.86)pg/ml(P<0.05)。两组的不良反应发生率比较差异无统计学意义(P>0.05)。结论阿立哌唑联合无抽搐电休克治疗难治性精神分裂症可显著提高患者治疗效果,在积极减轻症状的同时对调整炎症平衡、增强神经营养亦有良好作用,具有较好的安全性,值得研究推广。Objective To study the clinical effects of aripiprazole combined with modified electric convulsive therapy in the treatment of refractory schizophrenia.Methods 86 patients with refractory schizophrenia were divided into a test group and a control group according to randomized number table method,each with 43 cases.Both groups were treated with aripiprazole,and the test group was also treated with modified electric convulsive therapy.Both groups were compared in terms of treatment effects,symptom scores(positive symptoms,negative symptoms,and general psychopathological scores),serum neurotrophic factors[brain-derived neurotrophic factor(BDNF),nerve growth factor(NGF),neurotrophin-3(NT-3)],and serum inflammatory factors[interleukin-4(IL-4),interleukin-6(IL-6),interleukin-1β(IL-1β)],and the incidence of adverse reactions.Results The excellent rate of treatment of 69.77%in the test group was higher compared with 41.86%in the control group(P<0.05).After treatment,the scores of positive symptom,negative symptom,general psychopathology and total score in both groups were lower than those before treatment;the scores of positive symptom,negative symptom,general psychopathology and total score of the test group were(15.51±2.64),(13.62±2.88),(22.53±5.82)and(51.66±6.78)points,which were lower than(20.21±5.47),(18.69±4.75),(27.66±7.82)and(66.56±9.24)points in the control group(P<0.05).After treatment,the levels of BDNF,NGF and NT-3 in both groups were higher than those before treatment;the test group had BDNF of(14.05±2.56)μg/L,NGF of(46.77±9.21)μg/L and NT-3 of(170.82±22.61)pg/ml,which were higher than(11.18±1.97)μg/L,(38.69±8.41)μg/L and(151.63±20.74)pg/ml in the control group(P<0.05).After treatment,IL-4 level in both groups was higher than that before treatment,and IL-6 and IL-1βlevels were lower than those before treatment;the test group had higher IL-4 of(11.35±3.58)pg/ml than(9.52±2.64)pg/ml in the control group;the test group had IL-6 of(30.31±3.64)pg/ml and IL-1βof(26.85±3.62)pg/ml,which wer

关 键 词：难治性精神分裂症 无抽搐电休克 阿立哌唑 血清神经营养因子 血清炎症因子 不良反应 

分 类 号：R749.3[医药卫生—神经病学与精神病学]